Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — NANETS (November 2026)
15 slides from Perspective Therapeutics's conference presentation, Nov 6, 2026
Slide 1: Cohort-Level Safety and Efficacy Results for [212Pb]VMT-a-NET in Advanced SSTR2 NETs
NANETS | f) PERSPECTIVE Cohort-Level Safety and Efficacy Results for [?*7Pb] VMT-a-NET in Advanced Somatostatin Receptor S upeyP pe ee tS area Ssi Le St Neur roendocrine T Thorvardur Halfdanarson’, Vikas Prasad?, Vineeth Sukrithan*, Brandon Mancini*, Seyed Mosallaie®, Savitha Balaraman’®, Gregory Si
Slide 2: Declaration of Interests
Declaration of Interests Research support to institution: Thermo Fisher Scientific, Advanced Accelerator Applications (a Novartis company), Camurus, Crinetics, ITM Isotope Technologies Munich, RayzeBio (a Bristol Myers Squibb company), Perspective Therapeutics, Rezolute, Exelixis Consulting/Advisory
Slide 3: SSTR2-Targeting Alpha-Emitting Radiotherapies May Exhibit Improved Safety and Efficacy over Beta-Emitters
SSTR2-Targeting Alpha-Emitting Radiotherapies for Neuroendocrine Tumors May Exhibit Improved Safety and Efficacy over Beta-Emitters * SSTR2 is an established target in NETs, but patients progressing after somatostatin analogues have limited treatment options ¢ Alpha particles cause complex double-st
Slide 4: Pb-optimized chelator
Pb-optimized chelator 203Pb: imaging, diagnostics 212Pb: therapeutic a-radiation delivery [2°9Pb]VMT-a-NET [2?27Pb]VMT-a-NET 3h pi 3h p.i Coronal
Slide 5: Study Design
Study Design This is an ongoing, prospective, dose- finding/expansion, Phase 1/2a trial with pre-specified DLT monitoring and investigator-assessed RECIST v1.1 endpoints Median follow up = Unresectable or metastatic NET, Dose-Finding/Expansion Study 34 (11-59) weeks radiologic progression, on 21 Coh
Slide 6: Baseline Characteristics
Baseline Characteristics A pretreated, PRRT- e, heterogeneous NET popula charactor Cohort 1 Cohort 2 Cohort 3° Total N=2 N=46 N=20) N Age, median, years 65.5 61.5 62.5 62.5 Primary Cancer Diagnosis GI-NET, n (%) 2 (100) 23 (50.0) 9 (45.0) 34 (50.0) P-NET, n (%) 0 20 (43.5) 11 (55.0) 31 (45.6) GEP-NE
Slide 7: Safety: Overall
Safety: Overall + 56/68 (82%) received all four planned doses + TEAEs mostly Grade 1 or Grade 2; Grade 3 in 20 (29.4%); no Grade 4 or 5 within the TEAE window + No treatment-related SAEs or AE-related discontinuations within TEAE window * Favorable hematologic safety profile and no intervention requ
Slide 8: Renal Safety Over Time
Renal Safety Over Time Serum creatinine — Cohorts 1, 2 and 31 Grade 3 renal events were rare (2/68 patients) during . 1 Trferquare range (TAR): QT (26th percentie) to G3 (75th percentile) ongoing study follow up, possibly not drug related’ x Mean => “| 7 Lowestand highest values within 1.5 » IQR oft
Slide 9: Efficacy: Response Rates
Efficacy: Response Rates Objective Responses (PR + uPR) in Cohort 2 (33%) and Cohort 3 (50%), with disease control in 289% of patients in each cohort? Best overall response by cohort Cohort 1 | Cohort 2 | Cohort 3 (N=2) (N=46) ( 0) n(%) n (%) ) Disease control 2(100) 41 (89.1) ORR 0 15 (32.6) Confir
Slide 10: Efficacy: Durable Ongoing Disease Control
in patients 4 Durable ongoing disease c received at least one dose, with follow-up ongoing Efficacy: Durable Ongoing Disease Control SSTR2+ GE rol was observed across c 50 x ° & Percent Change from Baseline (%) ® g & 8 15 Cohort 2, subjects who received at least 1 dose Cohort 3, subjects who receive
Slide 11: Efficacy: Durable Ongoing Disease Control
Efficacy: Durable Ongoing Disease Control Durable ongoing disease control was observed across all cohorts in patients who received at least one dose ( Cohorts 1-3, All subjects receiving at least 1 dose (N=68) = =e a a = = = SS————————SSSSSSSSSSSSS—= = o = Z =e SSS = > —_—_—_———————_—_——_—_—_—_—_ —O
Slide 12: Efficacy: Progression-Free Survival
for mate of investigator-assessed PFS at follow-up remains limited in Coh Efficacy: Progression-Free Survival e Kaplan-Meier est horts 1 82.6% Cohort 2 PFS at 6 months hs was 71.5% 71.2% PFS at 12 months Kaplan-Meier estimate of PFS PFS by cohort — All patients in Cohorts 1-3 (N=68) 20 18 i 0 0) 01
Slide 13: Efficacy: Progression-Free Survival, SSTR2+ GEP-NET
Efficacy: Progression-Free Survival, SSTR2* GEP-NET? Across SSTR2+ GEP-NET patients in Cohorts 1-3 who received at least one dose ( 75.1% remained progression-free at 18 months 89.5% a 76.1% L] 73.2% PFS at 6 months PFS at 12 months PFS at 18 months Kaplan-Meier estimate of PFS \ Landmark PFS rate,
Slide 14: Conclusions and Next Steps
Conclusions and Next Steps Interim results from this ongoing, non-randomized Phase 1/2a dose-escalation/expansion study show durable ongoing disease control and encouraging responses - No Grade 4 or 5 TEAEs, treatment-related SAEs, or AE-related discontinuations within the defined TEAE window SAFETY
Slide 15: Acknowledgements
Acknowledgements Thank you to all participants in the VMT-a-NET-T101 trial and to all clinical trial investigators.